(UroToday.com) The CARD trial, presented at ESMO 2019, demonstrated a benefit with cabazitaxel chemotherapy with regards to radiographic progression-free survival and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed within 12-months of starting anti-androgen therapy with either enzalutamide or abiraterone. The presence of mutations in DNA-damage repair genes has been found in up to 30% of men with mCRPC, and a subset of these patients have genomic alterations associated with response to PARP inhibitor therapy. In this study, Dr. Mihaela Aldea presented work examining the activity of cabazitaxel in patients with or without defects in DNA damage repair (DDR) genes.